Form 8-K

8-K — Zeo ScientifiX, Inc.

Accession: 0001829126-26-008299

Filed: 2026-08-04

Period: 2026-08-04

CIK: 0001557376

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — zeoscientifix_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (zeoscientifix_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: zeoscientifix_8k.htm · Sequence: 1

false

0001557376

2026-08-04

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 4, 2026

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

Nevada

000-55008

47-4180540

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

3321 College Avenue, Suite 246

Davie, Florida

33314

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (888) 963-7881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class

Trading Symbol

Name of each exchange on which registered

None

N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,”

“ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.

Item

8.01 Other Events.

On August 4, 2026, ZEO issued a press release

announcing the launch of ZEO Xperience, the Company’s inaugural three-day immersive educational experience designed exclusively

for healthcare professionals seeking to expand their knowledge of regenerative biologics, strengthen clinical expertise, and learn best

practices for responsibly integrating advanced biologic therapies into patient care.

copy of the press release is included as Exhibit 99.1 to this Report.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.

Description

99.1

Press Release, dated August 4, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 4, 2026

ZEO SCIENTIFIX, INC.

By:

/s/ Ian T. Bothwell

Ian T. Bothwell

Chief Executive Officer and Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: zeoscientifix_ex99-1.htm · Sequence: 2

Exhibit 99.1

ZEO ScientifiX Launches First-of-Its-Kind ZEO

Xperience, a Three-Day Immersive

Regenerative Medicine Experience for Healthcare Professionals

Hosted at Fort Lauderdale’s newly reimagined

Pier Sixty-Six Resort, the inaugural event combines cutting-edge biologics education, hands-on clinical training, practice growth strategies,

and latest innovations.

DAVIE, FLORIDA — August 4, 2026

— ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO ScientifiX” or the “Company”), a biologics research and products

company advancing regenerative medicine, physician education, and next-generation biologic technologies, today announced the launch of

ZEO Xperience, the Company’s inaugural three-day immersive educational experience designed exclusively for healthcare professionals

seeking to expand their knowledge of regenerative biologics, strengthen clinical expertise, and learn best practices for responsibly integrating

advanced biologic therapies into patient care.

Taking place October 23–25, 2026,

at the newly reimagined Pier Sixty-Six Resort in Fort Lauderdale, Florida, ZEO Xperience will bring together physicians, nurse

practitioners, physician assistants, nurses, chiropractors, dentists, podiatrists, and other licensed healthcare professionals from across

the country for a first-of-its-kind educational experience centered on the science, clinical application, and the business of regenerative

medicine.

Designed to move beyond the traditional conference

event model, ZEO Xperience combines evidence-based scientific education with hands-on clinical learning, business development strategies,

collaborative networking, and immersive longevity experiences. Attendees will gain practical insights from industry experts while exploring

emerging technologies, innovative treatment approaches, and real-world strategies that can immediately be applied within their practices.

“Education has always been at the core of

ZEO ScientifiX’s mission,” said Ian Bothwell, Chief Executive Officer of ZEO ScientifiX. “As regenerative medicine continues

to evolve, healthcare professionals deserve educational experiences that go beyond lectures. ZEO Xperience was created to bring together

science, innovation, and practical implementation in an environment where attendees leave with the knowledge, confidence, and relationships

needed to elevate patient care and responsibly advance regenerative medicine.”

Sean Vega-Stanton, M.S., General Manager of ZEO

ScientifiX, added:

“From the moment we began planning ZEO Xperience,

our vision was to provide an event experience we felt was missing in this industry. We wanted to move beyond the traditional conference

model and build an immersive experience where healthcare professionals don’t just listen....they engage, collaborate, learn, and leave

with practical strategies they can immediately apply in their practices. Every detail, from the educational programming to the venue selection

and attendee participation, was intentionally designed to deliver an exceptional experience. We hope this becomes the event that healthcare

professionals look forward to attending year after year.”

The inaugural ZEO Xperience will feature three

immersive educational experiences:

Day One – Science & Innovation

Attendees will explore the latest advancements

in regenerative biologics through evidence-based presentations, physician-led discussions, clinical case studies, emerging research, and

expert panels focused on the future of regenerative medicine.

Day Two – Clinical Training & Practice

Growth

Healthcare professionals will participate in advanced

clinical education, live demonstrations, procedural training, practice development sessions, patient acquisition strategies, regulatory

discussions, and operational best practices designed to support successful implementation of regenerative medicine within clinical practice.

Day Three – Biohacking Experience

The conference concludes with an immersive exploration

of performance optimization and innovation, featuring interactive wellness technologies, recovery modalities, metabolic optimization,

and emerging tools that are helping shape the future of preventative and regenerative healthcare.

The launch of ZEO Xperience represents another

milestone in ZEO ScientifiX’s commitment to advancing physician education, scientific collaboration, and the responsible adoption of regenerative

biologic technologies. As interest in regenerative medicine continues to grow, the Company believes comprehensive, evidence-driven education

remains one of the most important drivers of improved patient outcomes, clinical excellence, and long-term practice success.

Attendance for the inaugural event is intentionally

limited to create a highly interactive educational environment and maximize opportunities for collaboration between attendees and faculty.

Registration is now open. For additional information

and to reserve your seat, visit www.zeoscientifix.com/xperience.

About ZEO ScientifiX (OTCQB: ZEOX)

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is an SEC-reporting,

clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. Operating

from Nova Southeastern University’s Center for Collaborative Research, the Company translates emerging science into scalable clinical

solutions through physician education, scientific collaboration, and innovative biologic technologies. ZEO ScientifiX supports clinicians

seeking to advance patient care while building sustainable regenerative medicine practices. For more information, visit www.zeoscientifix.com.

Forward-Looking Statements

Certain statements contained in this press release

should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange

Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and

unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are

reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could

vary materially. ZEO ScientifiX undertakes no obligation to update forward-looking statements except as required by applicable law.

Media Contact

Zeo ScientifiX,

Inc.

Ashley Simioneshci

1-888-963-7881

IR@zeoscientifix.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 04, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 04, 2026

Entity File Number

000-55008

Entity Registrant Name

ZEO SCIENTIFIX, INC.

Entity Central Index Key

0001557376

Entity Tax Identification Number

47-4180540

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3321 College Avenue

Entity Address, Address Line Two

Suite 246

Entity Address, City or Town

Davie

Entity Address, State or Province

Entity Address, Postal Zip Code

33314

City Area Code

(888)

Local Phone Number

963-7881

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration